Profile

Pioneers in proteomics data analysis reflect on what to focus on in computational biology.

John Storey provides his take on the importance of new statistical methods for high-throughput sequencing.

A trailblazer in the field of antibiotics reflects on natural product discovery in the genomic age.

Human genome pioneer David Haussler talks about the evolving role of annotated data repositories.

A research leader at a major agrochemical company comments on the application of biotechnologies in commercial crop science.

A decade after publishing the seminal “The hallmarks of cancer” paper in Cell with Doug Hanahan, Robert Weinberg reflects on where we stand in the fight against cancer.

An authority on hematopoiesis talks about the difficulties encountered in commercializing stem cell therapies.

The executive director of the Genome Institute of Singapore surveys the changing global landscape of healthcare provisioning.

A longtime investor, company founder, investment banker and industry observer discusses the factors shaping biotech financing.

An industry veteran talks about the challenges facing a world-leading pharmaceutical corporation.

Lee Hood outlines his vision of personalized medicine for the next 10 years.

Reflecting on progress in the bioenergy sector, Lee Lynd considers the prospects of producing liquid biofuels on a scale sufficient to impact energy challenges.

The inventor of humanized monoclonal antibodies and cofounder of Cambridge Antibody Technology, Greg Winter, muses on the future of antibody therapeutics and UK life science innovation.

The author of the landmark book Science Business: the Promise, the Reality and the Future of Biotech discusses key challenges in life science commercialization.

The man spearheading Pfizer's Centers for Therapeutic Innovation (CTI) initiative outlines how his company hopes to spur academia collaborations.

The former National Institutes of Health (NIH) director lays out the numerous challenges facing the translation of academic discoveries.

The executive director of the Deloitte Center for Healthcare Solutions discusses how the changing policy and reimbursement environment is likely to affect the biotech and pharmaceutical sectors.

Reflecting on the growth of bioinformatics over the past decade, the University of Pennsylvania's David Roos highlights the increasing diversity of large-scale data sets, changing paradigms for data release and the emergence of new career opportunities.